Navigation Links
Drug Improves Survival in Mice With Brain Tumors
Date:4/2/2009

Cediranib reduces tissue swelling better than steroids, team says

THURSDAY, April 2 (HealthDay News) -- Anti-angiogenesis drugs reduce edema (swelling of brain tissue) caused by deadly brain tumors called glioblastomas, a new study suggests.

Anti-angiogenesis drugs prevent the formation of new blood vessels that tumors need to grow, the researchers pointed out.

In this study, a Massachusetts General Hospital team found that the experimental anti-angiogenesis drug cediranib reduced edema and improved survival in mice with glioblastomas. The drug inhibits an angiogenesis factor called VEGF, which is abundant in glioblastomas.

"Our findings suggest that anti-angiogenesis therapy can increase patient survival even in the face of persistent tumor growth," study co-senior author Rakesh K. Jain, director of the Steele Laboratory in MGH's radiation oncology department, said in a hospital news release. "In glioblastoma clinical trials, it is important to separate survival analysis from that of tumor response to therapy, since many factors combine to cause patient deaths."

Previous research showed that cediranib temporarily normalized abnormal, leaky blood vessels that had recurred after surgery, radiation or chemotherapy for glioblastoma, reducing edema and the size of tumors. But exactly how the drug did this was unclear. This study clarified that cediranib's beneficial effects resulted from reduction of edema, the study authors said.

"This is the first paper to show that vascular normalization alone, without chemotherapy, can be effective against some tumors by controlling edema, and that this anti-edema effect is better than that of currently used steroids," Jain said.

"Unfortunately, these anti-VEGF agents did not slow the tumor growth rate in these [mouse] models; and since recurrent glioblastomas are highly resistant to currently used chemotherapy drugs, even if vascular normalization increased drug delivery, there may be little or no additional increase in patient survival. We urgently need to find better anti-tumor and anti-angiogenic agents."

The study, which was published online and is expected to be in a future print issue of the Journal of Clinical Oncology, received funding from AstraZeneca Pharmaceuticals, which manufactures cediranib under the brand name Recentin.

More information

The American Brain Tumor Association has more about brain tumors.



-- Robert Preidt



SOURCE: Massachusetts General Hospital, news release, March 30, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
2. Exercise and yoga improves quality of life in women with early-stage breast cancer
3. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
4. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
5. Kerry Extends, Improves Small Business Innovation Program
6. Thalidomide Improves Outcomes for Older Myeloma Patients
7. Grape Consumption Improves Antioxidant Capacity in Humans
8. JCSM: CPAP therapy improves symptoms of depression in OSA patients
9. Early intervention dramatically improves outcomes for new dialysis patients
10. New technique improves purity of medicines
11. Novel medication improves ovarian cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Improves Survival in Mice With Brain Tumors
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a dauntless and ... “End Time GPS” is the creation of published author, Wesley Gerboth, a World ... military munitions and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Adventures of Joey, ... and silly dog who lives his life to the fullest, as God intended. “The ... author Patti Holmgren, a mother and grandmother pursuing her passion for writing, especially about ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic ... greater Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., ... Village. This newest location will provide patients living in the north Houston area (The ...
(Date:3/23/2017)... NJ (PRWEB) , ... March 23, 2017 , ... ... Renaissance Oklahoma City Convention Center at 10 North Broadway Avenue, will be an ... hours of relevant, practical instruction in the management of chronic pain. , Oklahoma ...
(Date:3/23/2017)... ... 2017 , ... 82% of adults are unaware of the dangers that infectious bacteria play in ... minimum two times a day that dentists recommend. The ramifications of improper oral upkeep go ... and adults missing 164 million hours of work each year due to dental issues. That ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 24, 2017  GenomeDx Biosciences today announced that six ... Decipher® Prostate Cancer Classifier tests will be presented at ... (EAU) Congress held March 24 to 28, 2017 in ... Congress is Europe,s largest urological ... the urological field. The abstract titled "Muscle ...
(Date:3/24/2017)... BOTHELL, Wash. , March 23, 2017 /PRNewswire/ ... developer of advanced medical technology for non-invasive surgery, ... the Mirabilis System for treatment of uterine fibroids ... that it had received approval from the US ... study of the Mirabilis System in the United ...
(Date:3/24/2017)... Mar 24, 2017 The Board of Directors ... Annual Report 2016 including the complete 2016 Annual Accounts with ... on Nordic Nanovector,s website in the section Investor Relations/Reports and ... ... Tone Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
Breaking Medicine Technology: